Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Metabolic health — encompassing glucose metabolism, lipid profiles, insulin sensitivity, and cardiovascular risk markers — represents an investigational area for Urolithin A research. Unlike muscle endurance and mitochondrial biomarkers, the human metabolic evidence is limited and largely based on secondary endpoints or preclinical data. This page clearly labels this area as investigational and distinguishes between established preclinical findings and the limited human data available. The rationale for exploring metabolic outcomes is based on mitochondrial dysfunction's role in metabolic disease, not on clinical proof of benefit.
This Page Changed How You Think About Energy. Now Change How You Live.
Knowledge without action is just entertainment. Apply what you've learned and give your cells the support science says they need.
Detailed Evidence
SCIENTIFIC RATIONALE Mitochondrial dysfunction is implicated in metabolic diseases including type 2 diabetes, obesity-related insulin resistance, and non-alcoholic fatty liver disease (NAFLD). Since Urolithin A activates mitophagy — the clearance of damaged mitochondria — researchers hypothesize that it could improve metabolic function by restoring healthy mitochondrial pools in metabolically active tissues (liver, muscle, adipose tissue). PRECLINICAL METABOLIC DATA In preclinical models, Urolithin A has shown: (1) improved glucose tolerance and insulin sensitivity in high-fat diet mice, (2) reduced hepatic lipid accumulation in NAFLD models, (3) improved lipid profiles in rodents, and (4) enhanced mitochondrial function in metabolically stressed tissues. These effects are consistent with the mitophagy mechanism but represent animal data that may not translate to humans. HUMAN METABOLIC BIOMARKER DATA Published human trials have included some metabolic biomarkers as secondary endpoints: (1) The Singh 2022 trial reported changes in plasma acylcarnitines — markers of mitochondrial fatty acid metabolism — which improved in a dose-dependent manner. (2) No significant changes in fasting glucose, HbA1c, or standard lipid panels have been specifically reported in published UA trials. (3) Body weight and body composition did not change significantly in any published trial. CARDIOVASCULAR METABOLIC EVIDENCE The Denk 2025 Nature Communications study provided the most relevant metabolic evidence. The preclinical component showed cardioprotective effects and mitochondrial quality enhancement. A sub-analysis of human data suggested improvements in certain cardiovascular biomarkers. However, this study is primarily preclinical and the human component is a sub-analysis rather than a prospective cardiovascular trial. WHY THIS AREA REMAINS INVESTIGATIONAL The metabolic health evidence for UA is investigational for several reasons: (1) No human trial has been designed with metabolic outcomes as primary endpoints. (2) Published trials did not enroll participants with metabolic diseases. (3) Preclinical metabolic effects do not reliably predict human clinical outcomes. (4) The doses and duration required for metabolic benefits in humans are unknown.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
Your Future Self Will Thank You (Or Wonder Why You Waited)
Cellular damage is cumulative. The sooner you support your mitochondria, the more years of vitality you protect.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Does Urolithin A improve metabolic health?
The evidence is investigational. No human trial was designed with metabolic outcomes as primary endpoints. Preclinical models show benefits, but human metabolic data is limited to secondary endpoints. This area is hypothesis-generating, not evidence-supported.
Can Urolithin A help with type 2 diabetes?
Unknown. No trial enrolled participants with type 2 diabetes. Preclinical models show improved glucose tolerance, but this has not been tested in human diabetic populations. Consult a healthcare provider — UA is not a diabetes treatment.
Does Urolithin A affect blood sugar levels?
No significant changes in fasting glucose or HbA1c have been reported in any published UA trial. These were not primary endpoints. Preclinical data shows improved glucose tolerance, but human data is lacking.
Does Urolithin A improve cholesterol?
No significant changes in standard lipid panels have been reported in published UA trials. Preclinical models show improved lipid profiles, but this has not been confirmed in human studies.
Can Urolithin A help with fatty liver disease?
Preclinical NAFLD models show reduced hepatic lipid accumulation with UA. No human NAFLD studies have been conducted. This is investigational and UA is not a treatment for fatty liver disease.
Does Urolithin A cause weight loss?
No. Body weight and body composition did not change significantly in any published human UA trial. UA is not a weight loss intervention.
What metabolic biomarkers did UA trials measure?
Plasma acylcarnitines (mitochondrial fatty acid metabolism markers) improved dose-dependently. Standard metabolic markers (glucose, HbA1c, lipid panels) did not change significantly. Body weight/composition did not change.
Why is metabolic health listed as investigational?
No human trial was designed with metabolic primary endpoints, trials enrolled healthy (not metabolic disease) participants, preclinical effects don't reliably translate to humans, and required doses/duration for metabolic benefits are unknown.
Does Urolithin A improve insulin sensitivity?
Preclinical models show improved insulin sensitivity in high-fat diet mice. No human trial has measured insulin sensitivity as an endpoint. This remains investigational.
Is there cardiovascular metabolic evidence for Urolithin A?
The Denk 2025 Nature Communications study provided preclinical cardioprotective evidence with a human biomarker sub-analysis showing improvement. This is primarily preclinical with limited human sub-analysis — early-stage evidence.
Does Urolithin A affect metabolic syndrome?
No trial has studied metabolic syndrome. Preclinical data is promising, but no human data exists. UA is not a treatment for metabolic syndrome.
How does mitochondrial function relate to metabolism?
Mitochondria are central to glucose metabolism, fatty acid oxidation, and energy production. Mitochondrial dysfunction is implicated in type 2 diabetes, insulin resistance, and NAFLD — providing the rationale for studying mitophagy activators.
Could Urolithin A prevent metabolic disease?
Unknown. No trial has measured disease prevention. The rationale exists (mitochondrial dysfunction in metabolic disease), but no human evidence supports UA for metabolic disease prevention.
What preclinical metabolic data exists for Urolithin A?
Improved glucose tolerance and insulin sensitivity in high-fat diet mice, reduced hepatic lipid accumulation in NAFLD models, improved lipid profiles, and enhanced mitochondrial function in metabolically stressed tissues.
Should I take Urolithin A for metabolic health?
The metabolic evidence is investigational. No human trial supports UA for metabolic health outcomes. Decisions should be individualized with a healthcare provider. UA is not a treatment for metabolic diseases.
Key Research Facts
No human trial has been specifically designed to evaluate metabolic health outcomes for Urolithin A — all metabolic data comes from secondary endpoints or preclinical models.
Strong EvidenceD'Amico et al., Trends in Molecular Medicine — doi:10.1016/j.molmed.2021.04.009
Preclinical models show improved glucose tolerance and insulin sensitivity in high-fat diet rodent models treated with Urolithin A.
Moderate EvidenceD'Amico et al., Trends in Molecular Medicine — doi:10.1016/j.molmed.2021.04.009
Plasma acylcarnitines — markers of mitochondrial fatty acid metabolism — improved dose-dependently in human trials, but standard metabolic markers did not change significantly.
Strong EvidenceSingh et al., Cell Reports Medicine — doi:10.1016/j.xcrm.2022.100633
Body weight and body composition did not change significantly in any published human Urolithin A trial.
Strong EvidenceSingh et al., 2022; Liu et al., 2022 — doi:10.1016/j.xcrm.2022.100633
Preclinical data shows reduced hepatic lipid accumulation in NAFLD rodent models, but no human NAFLD studies have been conducted.
Moderate EvidenceD'Amico et al., Trends in Molecular Medicine — doi:10.1016/j.molmed.2021.04.009
The Denk 2025 Nature Communications study provided preclinical cardioprotective evidence with a sub-analysis of human cardiovascular biomarker improvements.
Emerging EvidenceDenk et al., Nature Communications — doi:10.1038/s41467-025-57067-3
Mitochondrial dysfunction is implicated in type 2 diabetes, obesity-related insulin resistance, and NAFLD — providing the rationale for studying mitophagy activators.
Strong EvidenceLópez-Otín et al., Cell — doi:10.1016/j.cell.2022.11.001
Published trials enrolled generally healthy participants — no individuals with metabolic diseases were specifically recruited.
Strong EvidenceJayatunga et al., Ageing Research Reviews — pubmed:39002645
No significant changes in fasting glucose, HbA1c, or standard lipid panels have been reported in any published Urolithin A human trial.
Strong EvidenceSingh et al., 2022 — doi:10.1016/j.xcrm.2022.100633
The metabolic health domain for Urolithin A should be considered hypothesis-generating, not evidence-supported, based on available data.
Strong EvidenceJayatunga et al., 2024 — pubmed:39002645
Citations & External Resources
ClinicalTrials.gov — Search: Urolithin A
FDA GRAS Notice GRN 000833 — Urolithin A
EFSA Novel Food Catalogue — Urolithin A
PubMed — Urolithin A research
Nature Medicine — Ryu et al. 2016 (Landmark Study)
JAMA Network Open — Liu et al. 2022 (Muscle Endurance RCT)
Nature Communications — Denk et al. 2025 (Cardiovascular/Metabolic)
PubMed — Urolithin A metabolic health research
NIH NIDDK — Metabolic Syndrome Information
The Most Important Health Decision You'll Make This Year
It's not a gym membership. It's not a diet. It's supporting the 37 trillion cells that make everything else possible.
Related Reading
Urolithin A & Mitochondrial Health: Evidence Summary
Urolithin A & Inflammatory Biomarkers: What Studies Report
Urolithin A & Healthy Aging: Research Context
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026